Literature DB >> 27041575

An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerases.

L Worrillow1, P Baskaran2, M A Care1, A Varghese3, T Munir3, P A Evans3, S J O'Connor3, A Rawstron3, L Hazelwood4, R M Tooze1, P Hillmen1, D J Newton1.   

Abstract

Chronic lymphocytic leukaemia (CLL) is the most common clonal B-cell disorder characterized by clonal diversity, a relapsing and remitting course, and in its aggressive forms remains largely incurable. Current front-line regimes include agents such as fludarabine, which act primarily via the DNA damage response pathway. Key to this is the transcription factor p53. Mutations in the TP53 gene, altering p53 functionality, are associated with genetic instability, and are present in aggressive CLL. Furthermore, the emergence of clonal TP53 mutations in relapsed CLL, refractory to DNA-damaging therapy, suggests that accurate detection of sub-clonal TP53 mutations prior to and during treatment may be indicative of early relapse. In this study, we describe a novel deep sequencing workflow using multiple polymerases to generate sequencing libraries (MuPol-Seq), facilitating accurate detection of TP53 mutations at a frequency as low as 0.3%, in presentation CLL cases tested. As these mutations were mostly clustered within the regions of TP53 encoding DNA-binding domains, essential for DNA contact and structural architecture, they are likely to be of prognostic relevance in disease progression. The workflow described here has the potential to be implemented routinely to identify rare mutations across a range of diseases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27041575     DOI: 10.1038/onc.2016.73

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  48 in total

1.  Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia.

Authors:  Elliot Stieglitz; Camille B Troup; Laura C Gelston; John Haliburton; Eric D Chow; Kristie B Yu; Jon Akutagawa; Amaro N Taylor-Weiner; Y Lucy Liu; Yong-Dong Wang; Kyle Beckman; Peter D Emanuel; Benjamin S Braun; Adam Abate; Robert B Gerbing; Todd A Alonzo; Mignon L Loh
Journal:  Blood       Date:  2014-11-13       Impact factor: 22.113

2.  TP53 mutation and survival in chronic lymphocytic leukemia.

Authors:  Thorsten Zenz; Barbara Eichhorst; Raymonde Busch; Tina Denzel; Sonja Häbe; Dirk Winkler; Andreas Bühler; Jennifer Edelmann; Manuela Bergmann; Georg Hopfinger; Manfred Hensel; Michael Hallek; Hartmut Döhner; Stephan Stilgenbauer
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

Review 3.  Clonal evolution in cancer.

Authors:  Mel Greaves; Carlo C Maley
Journal:  Nature       Date:  2012-01-18       Impact factor: 49.962

4.  Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

Authors:  Gerard Lozanski; Nyla A Heerema; Ian W Flinn; Lisa Smith; Jennifer Harbison; Jennifer Webb; Mollie Moran; Margaret Lucas; Thomas Lin; Marcy L Hackbarth; John H Proffitt; David Lucas; Michael R Grever; John C Byrd
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

5.  Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL).

Authors:  Natalia L Komarova; Jan A Burger; Dominik Wodarz
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-08       Impact factor: 11.205

6.  Dynamics of DNA damage induced pathways to cancer.

Authors:  Kun Tian; Ramkumar Rajendran; Manjula Doddananjaiah; Marija Krstic-Demonacos; Jean-Marc Schwartz
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

7.  Error Rate Comparison during Polymerase Chain Reaction by DNA Polymerase.

Authors:  Peter McInerney; Paul Adams; Masood Z Hadi
Journal:  Mol Biol Int       Date:  2014-08-17

8.  Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia.

Authors:  J Malcikova; K Stano-Kozubik; B Tichy; B Kantorova; S Pavlova; N Tom; L Radova; J Smardova; F Pardy; M Doubek; Y Brychtova; M Mraz; K Plevova; E Diviskova; A Oltova; J Mayer; S Pospisilova; M Trbusek
Journal:  Leukemia       Date:  2014-10-28       Impact factor: 11.528

9.  Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia.

Authors:  Jiguang Wang; Hossein Khiabanian; Davide Rossi; Giulia Fabbri; Valter Gattei; Francesco Forconi; Luca Laurenti; Roberto Marasca; Giovanni Del Poeta; Robin Foà; Laura Pasqualucci; Gianluca Gaidano; Raul Rabadan
Journal:  Elife       Date:  2014-12-11       Impact factor: 8.140

10.  Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.

Authors:  Terrence N Wong; Giridharan Ramsingh; Andrew L Young; Christopher A Miller; Waseem Touma; John S Welch; Tamara L Lamprecht; Dong Shen; Jasreet Hundal; Robert S Fulton; Sharon Heath; Jack D Baty; Jeffery M Klco; Li Ding; Elaine R Mardis; Peter Westervelt; John F DiPersio; Matthew J Walter; Timothy A Graubert; Timothy J Ley; Todd Druley; Daniel C Link; Richard K Wilson
Journal:  Nature       Date:  2014-12-08       Impact factor: 49.962

View more
  4 in total

Review 1.  Liquid biopsies in lung cancer-time to implement research technologies in routine care?

Authors:  Linda Köhn; Mikael Johansson; Kjell Grankvist; Jonas Nilsson
Journal:  Ann Transl Med       Date:  2017-07

2.  Cell Dispersal Influences Tumor Heterogeneity and Introduces a Bias in NGS Data Interpretation.

Authors:  Lőrinc Pongor; Hajnalka Harami-Papp; Előd Méhes; András Czirók; Balázs Győrffy
Journal:  Sci Rep       Date:  2017-08-04       Impact factor: 4.379

Review 3.  MtDNA As a Cancer Marker: A Finally Closed Chapter?

Authors:  Elmar Kirches
Journal:  Curr Genomics       Date:  2017-06       Impact factor: 2.236

4.  An optimized targeted Next-Generation Sequencing approach for sensitive detection of single nucleotide variants.

Authors:  S Stasik; C Schuster; C Ortlepp; U Platzbecker; M Bornhäuser; J Schetelig; G Ehninger; G Folprecht; C Thiede
Journal:  Biomol Detect Quantif       Date:  2018-01-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.